LNTH Lantheus Holdings, Inc.
FY2025 10-K
Lantheus Holdings, Inc. (LNTH) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development, manufacturing, and commercialization of radiopharmaceutical and diagnostic imaging products
- • New launches: Acquisitions of Life Molecular (Neuraceq) and Evergreen, adding diagnostic imaging and CDMO services to portfolio in 2025
Management Discussion & Analysis
- • Operating cash flow $390.1M in 2025 vs $544.8M in 2024, decrease driven by acquisitions and working capital timing
- • Investing cash outflow $627.1M in 2025 vs $204.5M in 2024, 2025 includes $268.9M for Evergreen and $306.7M for Life Molecular acquisitions
Risk Factors
- • No specific or timely regulatory or legal risk detailed in the text
- • No concrete geopolitical or macroeconomic threat exposure disclosed
Financial SummaryXBRL
Revenue
$1.5B
Net Income
$234M
Gross Margin
61.1%
Operating Margin
20.2%
Net Margin
15.2%
ROE
21.4%
Total Assets
$2.2B
EPS (Diluted)
$3.41
Operating Cash Flow
$390M
Source: XBRL data from Lantheus Holdings, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Lantheus Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.